The Human Apolipoprotein AV Gene Is Regulated by Peroxisome Proliferator-activated Receptor-α and Contains a Novel Farnesoid X-activated Receptor Response Element
Open accessThe DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
The newly identified apolipoprotein AV (apoAV) gene is a key player in determining plasma triglyceride concentrations. Because hypertriglyceridemia is a major independent risk factor in coronary artery disease, the understanding of the regulation of the expression of this gene is of considerable importance. We presently characterize the structure, the transcription start site, and the promoter of the human apoAV gene. Since the peroxisome proliferator-activated receptor-alpha (PPARalpha) and the farnesoid X-activated receptor (FXR) have been shown to modulate the expression of genes involved in triglyceride metabolism, we evaluated the potential role of these nuclear receptors in the regulation of apoAV transcription. Bile acids and FXR induced the apoAV gene promoter activity. 5'-Deletion, mutagenesis, and gel shift analysis identified a heretofore unknown element at positions -103/-84 consisting of an inverted repeat of two consensus receptor-binding hexads separated by 8 nucleotides (IR8), which was required for the response to bile acid-activated FXR. The isolated IR8 element conferred FXR responsiveness on a heterologous promoter. On the other hand, in apoAV-expressing human hepatic Hep3B cells, transfection of PPARalpha specifically enhanced apoAV promoter activity. By deletion, site-directed mutagenesis, and binding analysis, a PPARalpha response element located 271 bp upstream of the transcription start site was identified. Finally, treatment with a specific PPARalpha activator led to a significant induction of apoAV mRNA expression in hepatocytes. The identification of apoAV as a PPARalpha target gene has major implications with respect to mechanisms whereby pharmacological PPARalpha agonists may exert their beneficial hypotriglyceridemic actions.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



















Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Activation of PPARα increases the production of lipoprotein lipase (LPL) and apolipoprotein (apo) A-V, while it decreases the plasma levels of apo C-III that inhibits LPL activity, thereby enhancing the catabolism of TG-rich lipoproteins and reducing serum TG levels [31–34].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [32]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Peroxisome Proliferator-Activated Receptors: Nuclear Control of Metabolism*
Desvergne, B., & Wahli, W. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.5.0380 · Cited by 3,086
Identification of a nuclear receptor for bile acids
Makishima, M., Okamoto, A. Y., Repa, J. J., Tu, H., Learned, R. M., Luk, A., Hull, M. V., Lustig, K. D., Mangelsdorf, D. J., & Shan, B. (1999) · Science · doi:10.1126/science.284.5418.1362 · Cited by 2,714
Bile Acids: Natural Ligands for an Orphan Nuclear Receptor
Parks, D. J., Blanchard, S. G., Bledsoe, R. K., Chandra, G., Consler, T. G., Kliewer, S. A., Stimmel, J. B., Willson, T. M., Zavacki, A. M., Moore, D. D., et al. (1999) · Science · doi:10.1126/science.284.5418.1365 · Cited by 2,274
Roles of PPARs in health and disease
Kersten, S., Desvergne, B., & Wahli, W. (2000) · Nature · doi:10.1038/35013000 · Cited by 1,956
Targeted Disruption of the Nuclear Receptor FXR/BAR Impairs Bile Acid and Lipid Homeostasis
Sinal, C. J., Tohkin, M., Miyata, M., Ward, J. M., Lambert, G., & Gonzalez, F. J. (2000) · Cell · doi:10.1016/s0092-8674(00)00062-3 · Cited by 1,819
Mechanism of Action of Fibrates on Lipid and Lipoprotein Metabolism
Staels, B., Dallongeville, J., Auwerx, J., Schoonjans, K., Leitersdorf, E., & Fruchart, J.-C. (1998) · Circulation · doi:10.1161/01.cir.98.19.2088 · Cited by 1,786
Endogenous Bile Acids Are Ligands for the Nuclear Receptor FXR/BAR
Wang, H., Chen, J., Hollister, K., Sowers, L. C., & Forman, B. M. (1999) · Molecular Cell · doi:10.1016/s1097-2765(00)80348-2 · Cited by 1,636
Identification of a nuclear receptor that is activated by farnesol metabolites
Forman, B. M., Goode, E., Chen, J., Oro, A. E., Bradley, D. J., Perlmann, T., Noonan, D. J., Burka, L. T., McMorris, T., Lamph, W. W., et al. (1995) · Cell · doi:10.1016/0092-8674(95)90530-8 · Cited by 1,210
Schoonjans, K., Peinado‐Onsurbe, J., Lefebvre, A. M., Heyman, R. A., Briggs, M., Deeb, S., Staels, B., & Auwerx, J. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00918.x · Cited by 1,173
Research works printed but not linked: 2
- Desvergne, B., and Wahli, W. (1999) Endocr. Rev. 20, 649 -688
- Applied Biosystems (2001) User Bulletin 2, Foster City, CA
Cited by
Items 101–200 of 200
Downing, L. E., Edgar, D., Ellison, P. A., & Ricketts, M. (2017) · Cell Biochemistry and Function · doi:10.1002/cbf.3247 · Cited by 31
“This induction in LPL expression reflects the presence of a PPRE in the promoter region of the gene coding for this enzyme52 and also the ability of PPARα to indirectly inhibit apolipoprotein c‐III, which is an LPL repressor.45,53 Additionally, PPARα upregulates expression of Apolipoprotein A5 (APOA5), which decreases…”
BackgroundAssociation of human serum apolipoprotein A5 with lipid profiles affected by gender
Zhao, S., Hu, S., Li, J., Hu, M., Liu, Q., Wu, L., & Zhang, T. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.07.014 · Cited by 30
The Farnesoid X Receptor A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism
Rader, D. J., Hama, S. Y., Hough, G. P., Yu, N., & Ansell, B. J. (2005) · Cited by 29
Estrogen lowers triglyceride via regulating hepatic APOA5 expression
Luo, F., Guo, Y., Ruan, G., Peng, R., & Li, X. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0463-0 · Cited by 32
Regulation of human class I alcohol dehydrogenases by bile acids
Langhi, C., Pedraz‐Cuesta, E., Haro, D., Marrero, P. F., & Rodríguez, J. C. (2013) · Journal of Lipid Research · doi:10.1194/jlr.m039404 · Cited by 29
Self-citationIdentification of the human ApoAV gene as a novel RORα target gene
Lind, U., Nilsson, T., McPheat, J., Strömstedt, P.-E., Bamberg, K., Balendran, C. A., & Kang, D. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.02.151 · Cited by 28
Alborn, W. E., Johnson, M. G., PRINCE, M. J., & Konrad, R. J. (2006) · Clinical Chemistry · doi:10.1373/clinchem.2005.061374 · Cited by 28
Zhu, J., Xu, K., Zhang, X., Cao, J., Jia, Z., Yang, R., Ma, C., Chen, C., Zhang, T., & Yan, Z. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.10.099 · Cited by 28
The role of apolipoprotein A 5 in obesity and the metabolic syndrome
Zheng, X., Zhao, S., & Yan, H. (2012) · Biological reviews/Biological reviews of the Cambridge Philosophical Society · doi:10.1111/brv.12005 · Cited by 28
“…peroxisome proliferator-activated receptor α (PPARα) (Prieur, Coste & Rodriguez, 2003; Vu-Dac et al., 2003), farnesoid X-activated receptor (FXR) (Prieur et al., 2003), retinoid acid receptor-related orphan receptor (ROR) (Genoux et al., 2005), hepatocyte nuclear factor 4 (HNF4) (Prieur et…”
., Y. P., Zhang, L., Yang, Q., Li, B., Guo, L., Fang, C., Gao, C., Wang, J., Xiang, J., & Li, J.-C. (2012) · Cerebrovascular Diseases · doi:10.1159/000338781 · Cited by 26
Cardona, F., Guardiola, M., Queipo‐Ortuño, M. I., Murri, M., Ribalta, J., & Tinahones, F. J. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.02.024 · Cited by 26
Zinc finger protein ZNF202 structure and function in transcriptional control of HDL metabolism
Schmitz, G., Heimerl, S., & Langmann, T. (2004) · Current Opinion in Lipidology · doi:10.1097/00041433-200404000-00013 · Cited by 29
Fuior, E. V., Zvintzou, E., Filippatos, T. D., Giannatou, K., Mparnia, V., Simionescu, M., Gafencu, A. V., & Kypreos, K. E. (2023) · Biomedicines · doi:10.3390/biomedicines11102696 · Cited by 28
“In addition, the group led by Rodriguez determined that in human HepG2 cells and primary hepatocytes isolated from cynomolgus liver GW9003 PPAR α agonists increase the APOA5 gene expression [48].”
Association of PPARα gene polymorphisms and lipid serum levels in a Brazilian elderly population
Chen, E., Mazzotti, D. R., Furuya, T. K., Cendoroglo, M. S., Ramos, L. R., Araújo, L. Q., Burbano, R. M. R., & Smith, M. D. A. C. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.10.001 · Cited by 25
“Once activated, PPARα binds to retinoid X receptor α to form a heterodimer, which recognizes specific DNA sequence elements, located in the promoter region of target genes (Prieur et al., 2003).”
BackgroundPalermo, F. A., Cocci, P., Mozzicafreddo, M., Arukwe, A., Angeletti, M., Aretusi, G., & Mosconi, G. (2015) · Toxicology Research · doi:10.1039/c5tx00314h · Cited by 25
An insight to treat cardiovascular diseases through phytochemicals targeting PPAR-α
Sharma, S., Sharma, D., Dhobi, M., Wang, D., & Tewari, D. (2023) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-023-04755-7 · Cited by 30
ApoA-V: The Regulation of a Regulator of Plasma Triglycerides
Olofsson, S. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000167518.27125.b1 · Cited by 22
Alborn, W. E., PRINCE, M. J., & Konrad, R. J. (2006) · Clinica Chimica Acta · doi:10.1016/j.cca.2006.11.009 · Cited by 20
The Expression of Intact and Mutant Human apoAI/CIII/AIV/AV Gene Cluster in Transgenic Mice
Gao, J., Wei, Y., Huang, Y., Liu, D., Liu, G., Wu, M., Wu, L., Zhang, Q.-J., Zhang, Z., Zhang, R., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m409883200 · Cited by 20
Sousa, M. O., Alia, P. J., Pintó, X., Corbella, E., & Navarro, M.-Á. (2008) · Clinica Chimica Acta · doi:10.1016/j.cca.2008.05.009 · Cited by 22
Orphan nuclear receptor Nur77 participates in human apolipoprotein A5 gene expression
Song, K. H. (2010) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.12.168 · Cited by 19
Association of apolipoprotein A5 gene promoter region −1131T>C with risk of stroke in Han Chinese
Li, X., Su, D.-F., Zhang, X., & Zhang, C. (2010) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2010.07.012 · Cited by 18
“The presence of naturally existing polymorphisms can modify the effect of APOA5 on the lipid metabolism, which can result in increased triglyceride levels [19,20].”
BackgroundDifferential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha
Prieur, X., Lesnik, P., Moreau, M., Rodríguez, J. C., Doucet, C., Chapman, M. J., & Huby, T. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.03.015 · Cited by 18
Self-citationThe Hyplip2 locus causes hypertriglyceridemia by decreased clearance of triglycerides
Moen, C. J. A., Tholens, A., Voshol, P. J., de Haan, W., Havekes, L. M., Gargalovic, P. S., Lusis, A. J., van Dijk, K. W., Frants, R. R., Hofker, M. H., et al. (2007) · Journal of Lipid Research · doi:10.1194/jlr.m700009-jlr200 · Cited by 20
Sanoudou, D., Duka, A., Drosatos, K., Hayes, K. C., & Zannis, V. I. (2009) · The Pharmacogenomics Journal · doi:10.1038/tpj.2009.51 · Cited by 18
Guardiola, M., Oliva, I., Guillaumet, A., Martín-Trujillo, Á., Rosales, R., Vallvé, J.-C., Sabench, F., Déjardin, D. D. C., Zaina, S., Monk, D., et al. (2014) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2014.10.029 · Cited by 18
Glucose Regulates the Expression of the Apolipoprotein A5 Gene
Nowak, M., Helleboid‐Chapman, A., Jäkel, H., Moitrot, E., Rommens, C., Pennacchio, L. A., Fruchart‐Najib, J., & Fruchart, J. (2008) · Journal of Molecular Biology · doi:10.1016/j.jmb.2008.04.057 · Cited by 17
Carboxyl-terminal sequences in APOA5 are important for suppressing ANGPTL3/8 activity
Chen, Y., Yang, Y., Zhen, Y., Beyer, T. P., Li, H., Wen, Y., Ehsani, M. E., JACKSON, N. J., Xie, K., Jung, H., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2322332121 · Cited by 17
Liao, X., Ma, Q., Wu, T., Shao, C., Lin, Y., Sun, Y., Feng, S., Wang, W., Ye, J., & Zhong, B. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s356371 · Cited by 15
Dorfmeister, B., Brandlhofer, S., Schaap, F. G., Hermann, M., Fürnsinn, C., Hagerty, B., Stangl, H., Patsch, W., & Strobl, W. (2006) · Diabetologia · doi:10.1007/s00125-006-0171-1 · Cited by 16
Becker, S., Schomburg, L., Renko, K., Tölle, M., van der Giet, M., & Tietge, U. J. F. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.105 · Cited by 15
Shou, W., Wang, Y., Xie, F., Wang, B., Yang, L., Wu, H. Y., Wang, Y., Wang, Z., Shi, J., & Huang, W. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2014.08.006 · Cited by 15
de Luis, D. A., Izaola, O., & Primo, D. (2021) · Disease Markers · doi:10.1155/2021/1257145 · Cited by 13
PPARα polymorphisms as risk factors for dyslipidemia in a Brazilian population
Mazzotti, D. R., Singulane, C. C., Ota, V., Rodrigues, T. P., Furuya, T. K., de Souza, F. J., Cordeiro, B. G., Magalhães, C. M. G., Chen, E., Jacomini, A., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.11.156 · Cited by 12
“Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in the regulation of several biochemical pathways such as lipid and carbohydrate metabolism, lipoprotein synthesis, adipogenesis and insulin sensitivity [5,6].”
BackgroundFibrate Pharmacogenomics: Expanding Past the Genome
House, J. S., & Motsinger‐Reif, A. A. (2020) · Pharmacogenomics · doi:10.2217/pgs-2019-0140 · Cited by 12
Takahashi, Y., Seko, Y., Yamaguchi, K., Takeuchi, K., Yano, K., Kataoka, S., Moriguchi, M., & Itoh, Y. (2023) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16222 · Cited by 12
Cholesterol homeostasis in ABCA1/LCAT double-deficient mouse
Hossain, M. A., Tsujita, M., Akita, N., Kobayashi, F., & Yokoyama, S. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2009.08.009 · Cited by 11
Li, X., Gong, H.-R., Huang, X., Huang, W., & Zhao, S. (2013) · Lipids in Health and Disease · doi:10.1186/1476-511x-12-133 · Cited by 12
“A PPAR response element has been identified at the transcription start site of apoA5 gene, whereby pharmacological PPAR agonists (such as fibrates) may exert their beneficial hypotriglyceridemic actions [6,7].”
BackgroundLipid‐activated nuclear receptors: from gene transcription to the control of cellular metabolism
Crestani, M., Mitro, N., & Fabiani, E. D. (2004) · European Journal of Lipid Science and Technology · doi:10.1002/ejlt.200300936 · Cited by 12
Zhai, G., Li, M., & Chaowang, Z. (2010) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm.2011.070 · Cited by 10
How to modulate FXR activity to treat the Metabolic Syndrome
Prawitt, J., Caron, S., & Staels, B. (2009) · Drug Discovery Today Disease Mechanisms · doi:10.1016/j.ddmec.2010.05.002 · Cited by 10
Zhang, L., Sato, H., Yang, Q., Ryan, R. O., Wang, D. Q. ‐., Howles, P. N., & Tso, P. (2015) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00227.2015 · Cited by 10
de Luis, D. A., Izaola, O., Primo, D., & Aller, R. (2021) · Annals of Nutrition and Metabolism · doi:10.1159/000517500 · Cited by 10
Zhang, H., Yang, C., Wang, S., Xu, A., Zhang, Q., Duan, X., Gong, G., & Wang, Y. (2023) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2023.5244 · Cited by 9
de Luis, D. A., Primo, D., Izaola, O., & Aller, R. (2022) · Nutrients · doi:10.3390/nu14122427 · Cited by 9
“This decreased clearance of TG in carriers of the C allele may produce a decrease in APOA5 function.”
BackgroundInfluentialRuiz-Narváez, E., & Campos, H. (2008) · Journal of Human Genetics · doi:10.1007/s10038-008-0245-7 · Cited by 10
“Even though it is known that expression of the APOA5 gene is regulated through different mechanisms (Prieur et al. 2003; Genoux et al. 2005; Nowak et al. 2005), it remains to be determined why plasma concentration of apoAV is substantially lower compared to concentrations of other apolipoproteins…”
BackgroundSeely, E. W., & Grinspoon, S. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-802101-9.00002-8 · Cited by 11
The APOA1/C3/A4/A5 cluster and markers of allostatic load in the Boston Puerto Rican Health Study
Mattei, J., Demissie, S., Tucker, K. L., & Ordovás, J. M. (2010) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2010.02.024 · Cited by 10
“Although the mechanisms of effect for the APOA1/C3/A4/A5 cluster polymorphisms are not yet clear and are likely complex, possible mechanisms include differential response to circulating apolipoproteins (27), impaired ribosomal translation efficiency (28), or regulation through PPAR or thyroid hormones (29,30).”
BackgroundKim, O. Y., Moon, J., Jo, G., Kwak, S., Kim, J. Y., & Shin, M. (2018) · Nutrition Research and Practice · doi:10.4162/nrp.2018.12.1.61 · Cited by 9
“Alternatively, a peroxisome proliferator response element in the promoter region of APOA5 was identified as a target gene for peroxisome proliferator-activated receptor-α (PPARα) [28].”
BackgroundSong, K. H., Park, A.-Y., Kim, J., & Yeul, J. (2013) · BioMed Research International · doi:10.1155/2013/892491 · Cited by 8
Gene–Diet Interactions and Obesity Indices
Papoutsakis, C. (2012) · Current Nutrition Reports · doi:10.1007/s13668-012-0019-x · Cited by 8
Regulation of N-Myc downstream regulated gene 2 by bile acids
Langhi, C., Pedraz‐Cuesta, E., Donate, Y., Marrero, P. F., Haro, D., & Rodríguez, J. C. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.03.058 · Cited by 9
Self-citationImpacto de la apolipoproteína A5 en el riesgo cardiovascular: Modulaciones genéticas y ambientales
Sotos‐Prieto, M., Francès, F., & Corella, D. (2010) · Revista médica de Chile · doi:10.4067/s0034-98872010000700013 · Cited by 9
Nakajima, H., Tsuma, Y., Fukuhara, S., & Kodo, K. (2022) · Journal of the Endocrine Society · doi:10.1210/jendso/bvac005 · Cited by 7
“Activation of PPARα increases the production of LPL and ApoA-V in the liver, while it decreases the circulating apoprotein C-III, which inhibits LPL activity, thereby enhancing the catabolism of TG-rich lipoproteins and reducing serum TG levels [20-22].”
BackgroundHelleboid‐Chapman, A., Nowak, M., Helleboid, S., Moitrot, E., Rommens, C., Dehondt, H., Héliot, L., Drobecq, H., Fruchart‐Najib, J., & Fruchart, J. (2009) · Cellular Physiology and Biochemistry · doi:10.1159/000257484 · Cited by 7
Li, Y., Wei, Y.-S., Fu, X., Hao, D., Xue, Z., Gong, H., Zhang, Z., Liu, D., & Liang, C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m710289200 · Cited by 7
ATVB In Focus: Novel Approaches to the Treatment of Dyslipidemia
Rader, D. J. (2005) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000154483.28595.a3 · Cited by 7
Apolipoprotein AV: gene expression,physiological role in lipid metabolism and clinical relevance
Prieur, X., Huby, T., Rodríguez, J. C., Couvert, P., & Chapman, J. (2008) · Future Lipidology · doi:10.2217/17460875.3.4.371 · Cited by 5
Self-citationVaessen, S., Sierts, J. A., Kuivenhoven, J., & Schaap, F. (2009) · Biochemical and Biophysical Research Communications - BBRC · doi:10.1016/j.bbrc.2008.12.115 · Cited by 6
“…both haplotypes 2 and 3 have consistently been associated with increased TG levels, the SNPs defining haplotype 2 appear to be non-functional 15-18 and the association of this haplotype with elevated TG levels appears to be associated with strong linkage disequilibrium with SNPs in the…”
Srivastava, R. A. K., Hurley, T. R., Oniciu, D. C., Adeli, K., & Newton, R. S. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.05.024 · Cited by 5
Interaction Between Ator and Fennel in the Treatment of Obesity in Rats
El-Ghazaly, N. A., Radwan, E., Zaatout, H. H., Elghazaly, M. M., & Allam, N. E. (2019) · Journal Of Obesity Management · doi:10.14302/issn.2574-450x.jom-19-2852 · Cited by 7
Yang, Y., Walijee, S. M., Jing, J., Zhao, S., & Peng, D. (2012) · Journal of clinical lipidology · doi:10.1016/j.jacl.2012.02.004 · Cited by 3
Hypertriglyceridemia in obese subjects: Caused by reduced apolipoprotein A5 plasma levels?
Heeren, J., & Merkel, M. (2010) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2010.06.020 · Cited by 3
Chapter 1 Regulation of Metabolism by Nuclear Hormone Receptors
Huang, H.-J., & Schulman, I. G. (2009) · Progress in molecular biology and translational science · doi:10.1016/s1877-1173(09)87001-4 · Cited by 4
Effects of fenofibrate on angiopoietin-like 3/4/8 proteins and apolipoprotein A5
Yang, Y., Smith, S. A., Chen, Y. Q., Li, H., Zhen, E. Y., Sloan, J. H., Siegel, R. W., Qian, Y., Wen, Y., Jung, H., et al. (2026) · Journal of Lipid Research · doi:10.1016/j.jlr.2026.101050 · Cited by 2
“PPAR α agonists have been reported to increase APOA5 transcripts in HepG2 cells and cynomolgus macaque hepatocytes (83, 84); they have also been reported to increase Apoa5 transcripts in mouse liver (85).”
Transcriptomics of a cytoglobin knockout mouse: Insights from hepatic stellate cells and brain
Porto, E., Backer, J. D., Thủy, L. T. T., Kawada, N., & Hankeln, T. (2023) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2023.112405 · Cited by 3
Elucidating the mechanism behind the lipid-raising effect of cafestol
Boekschoten, M. V. (2004) · doi:10.18174/39059 · Cited by 3
Les anticholestérolémiants, nouvelles approches thérapeutiques
Fruchart, J., & Duriez, P. (2004) · Annales Pharmaceutiques Françaises · doi:10.1016/s0003-4509(04)94276-9 · Cited by 3
Bai, L., Zhao, S., Huang, X., & Zhang, Q. (2008) · Bioscience hypotheses · doi:10.1016/j.bihy.2008.08.007 · Cited by 2
Investigation of the effects and mechanisms of endogenous deletion of FGF21 on cognitive functions
Jiang, Z., Tian, X., Sun, M., Yuan, H.-Z.-X., Xiang, S.-R., Zhang, H.-F., Zhang, J.-P., Cui, L.-Y., & Wang, W. (2025) · Physiology & Behavior · doi:10.1016/j.physbeh.2025.115174 · Cited by 1
PPAR-α and atherosclerosis from basic research to clinical applications
Fruchart, J., & Duriez, P. (2004) · International Congress Series · doi:10.1016/j.ics.2004.01.051 · Cited by 1
Siewert, S., Nicotra, M. F. O., González, I., Fernandez, G., & Ojeda, M. S. (2014) · OALib · doi:10.4236/oalib.1100967 · Cited by 1
“Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors involved in the regulation of several biochemical pathways such as lipid and carbohydrate metabolism, lipoprotein synthesis, adipogenesis and insulin sensitivity [9] [10].”
BackgroundThe expression of the human apolipoprotein genes and their regulation by PPARs
Juuso, U. (2008) · Cited by 2
Moreno‐Indias, I., Tinahones, F. J., Clemente‐Postigo, M., Castellano‐Castillo, D., Fernández‐García, J. C., Macías‐González, M., Queipo‐Ortuño, M. I., & Cardona, F. (2017) · Clinical Endocrinology · doi:10.1111/cen.13320 · Cited by 1
Statins Induce the Gene Expression of Apolipoprotein A5 in HepG2 Cells
Arishima, H., Matsunaga, A., Uehara, Y., Niimura, H., Zhang, B., Ohwaki, K., Hayashida, K., Yoshimizu, K., & Saku, K. (2011) · Institutional Repositories DataBase (IRDB) · Cited by 1
El gen de la apolipoproteína A5 se expresa en el intestino humano
Guardiola, M., Álvaro, A., Vallvé, J.-C., Rosales, R., Masana, L., & Ribalta, J. (2008) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(08)72598-1 · Cited by 1
Soro‐Paavonen, A. (2004) · Helda - University of Helsinki Institutional Repository · Cited by 1
Identificación de nuevos genes diana del receptor nuclear FXR
Cuesta, E. P. (2012) · Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona)
Liu, X. (2014) · UKnowledge (University of Kentucky)
Pampín, S., García‐Bailo, B., Ordovás, J. M., & Rodríguez-Rey, J. C. (2009) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(09)71129-5
Guardiola, M., Tous, M., Vallvé, J.-C., Rull, A., Masana, L., Joven, J., & Ribalta, J. (2007) · Clínica e Investigación en Arteriosclerosis · doi:10.1016/s0214-9168(07)74167-0
“La expresión hepática de APOA5 se correlaciona con parámetros inflamatorios como la concentra-ción en plasma de MCP-1 y con la superficie de le-sión arteriosclerótica.”
Function and regulation of the human bile salt export pump
Plass, J. R. M. (2005) · University of Groningen research database (University of Groningen / Centre for Information Technology)
Identification of a new binding partner of chicken apolipoprotein A-V
Bauer, R. (2009) · University of Vienna · doi:10.25365/thesis.3354
Novel factors affecting clearance of triacylglycerol-rich lipoproteins from blood
Nilsson, S. K. (2010)
Claudel, T., Sturm, E., Staels, B., & Kuipers, F. (2003) · CRC Press eBooks · doi:10.3109/9780203481165-8
The Role Of Crebh In Hepatic Energy Regulation Under Metabolic Stress
Mendez, R. (2015) · Human Biology
Investigations of the Mechanisms of Diabetes Remission: A Focus on Adaptive Thermogenesis
Corley, B. (2019) · Otago University Research Archive (University of Otago) · Cited by 2
Regulation of Lipoprotein Lipase Activity : an In-vitro Study of a Complex and Dynamic System
Kovrov, O. (2019) · DiVA at Umeå University (Umeå University)
Prochaska, C. L. (2006) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Implication de l'apolipoprotéine AV dans le déterminisme des hyperchylomicronémies
Charrière, S., Moulin, P., métaboliques, N. E. D. R. R., & Sciences-Santé, É. D. I. (2009) · OpenGrey (Institut de l'Information Scientifique et Technique)
Claudel, T., Sturm, E., Staels, B., & Kuipers, F. (2003) · CRC Press eBooks · doi:10.3109/9780203492444-8
Rodríguez, I. O. (2017) · LA Referencia (Red Federada de Repositorios Institucionales de Publicaciones Científicas)
Akbar, S. (2013) · theses.fr (ABES) · doi:10.70675/12cbed3ezfbadz4a56z9b85z48a11a6338e1
“In contrast, the endogenous lipid transport involves the production of VLDL by the liver and their hydrolysis by LPL to form IDL and LDL.”
InfluentialInfluence of bile acids metabolism on hepatic immunity in mice
Guinot, V. (2022) · theses.fr (ABES) · doi:10.70675/b69bb11eza30fz4874z9af2za6e31b2d5ad8
BindingDB Entry 50037531: Farnesoid X receptor: from structure to potential clinical applications.
BindingDB (2012) · UC San Diego · doi:10.7270/q2n29xq6
Destro, M. (2011) · Americanae (AECID Library)
Metadata
- Authors
- Prieur, X., Coste, H., & Rodríguez, J. C.
- Affiliations
- GlaxoSmithKline (France) (FR)
- Corresponding author
- Rodríguez, Joan C.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-07
- Volume
- 278
- Issue
- 28
- Pages
- 25468-25480
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2032849264
- Cited by
- 194
- References
- 55
- Citations by year
- 2026: 1 · 2025: 3 · 2024: 2 · 2023: 6 · 2022: 6 · 2021: 6 · 2020: 4 · 2019: 4 · 2018: 4 · 2017: 5 · 2016: 4 · 2015: 8 · 2014: 8 · 2013: 5 · 2012: 6
- FWCI
- 7.47
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6302 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- RECERCAT (Consorci de Serveis Universitaris de Catalunya) (submittedVersion)
- Dipòsit Digital de la Universitat de Barcelona (Universitat de Barcelona) (submittedVersion, public-domain)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- PPARα, farnesoid X receptor, bile acids, transcriptional regulation, promoter structure, transcription start sites, hypertriglyceridemia, hepatic gene expression, PPARα agonist, hypotriglyceridemic effect, triglyceride metabolism
- MeSH terms
- Apolipoprotein A-V, Receptor, Farnesoid X-Activated, Apolipoproteins, Apolipoproteins A, Base Sequence, Cell Line, Cell Nucleus, Chromosome Mapping, DNA-Binding Proteins, Exons, Carcinoma, Hepatocellular, Humans, Introns, Luciferases, Models, Genetic, Molecular Sequence Data, Mutation, Plasmids, DNA Ligases, Promoter Regions, Genetic, RNA, Messenger, Transcription Factors, Transcription, Genetic, Transfection, Protein Biosynthesis, Transcriptional Activation, Mutagenesis, Site-Directed, Gene Deletion, Receptors, Cytoplasmic and Nuclear, Receptors, Retinoic Acid, Dimerization, 5' Untranslated Regions, Reverse Transcriptase Polymerase Chain Reaction, Response Elements, Hepatocytes, Retinoid X Receptors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.